GSK plc with ticker (LON:GSK) now has a potential upside of 16.5% according to Deutsche.
Deutsche set a target price of 1,700 GBX for the company, which when compared to the GSK plc share price of 1,459 GBX at opening today (09/05/2023) indicates a potential upside of 16.5%. Trading has ranged between 1,281 (52 week low) and 3,408 (52 week high) with an average of 6,777,472 shares exchanging hands daily. The market capitalisation at the time of writing is £59,000,473,839.
GSK plc is a global biopharma company. The Company makes vaccines and specialty medicines to prevent and treat disease. Its segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed a new monoclonal antibody treatment for COVID-19. Its product areas include vaccines, specialty medicines, and general medicines. Its vaccine portfolio includes more than 20 vaccines that help protect people from a range of diseases and infections throughout their lives. Its specialty medicines include medicines for immune-mediated conditions, including the chronic autoimmune condition lupus, respiratory disease, and human immunodeficiency virus (HIV). Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease (COPD), antibiotics and medicines for skin diseases. It has a global network of about 12 vaccines manufacturing sites.
GSK plc 16.5% potential upside indicated by Deutsche
- Written by: Charlotte Edwards
Find more news, interviews, share price & company profile here for:
GSK announces the EMA's review of Nucala (mepolizumab) as a potential add-on treatment for COPD, promising hope for 40 million patients battling this condition.
GSK plc has completed its acquisition of IDRx, Inc., aiming to advance treatments for gastrointestinal stromal tumours with the novel IDRX-42 inhibitor.
GSK's Penmenvy vaccine wins FDA approval, offering protection for ages 10-25 against five major meningococcal serogroups, aiming to boost vaccination rates.
GSK plc reports robust 2024 performance with strong Specialty Medicines growth, promising R&D advancements, and strategic shareholder returns.
GSK's depemokimab, an ultra-long-acting biologic, is up for regulatory review in China and Japan for asthma and CRSwNP, based on positive trial results.
GSK's innovative prefilled Shingrix syringe gains EMA review, aiming to simplify shingles prevention for healthcare professionals across Europe.
